MedTrace Logo

Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel

NCT03100734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 585

Last updated 2021-02-05

No results posted yet for this study

Summary

The primary objective is to evaluate the effectiveness of Benepali in participants with Rheumatoid Arthritis (RA) and axial spondyloarthritis (axSpA), including participants with Ankylosing Spondylitis (AS) and non-radiographic axSpA, following their transition from treatment with Enbrel.

The secondary objectives of this study are to describe clinical characteristics of patients transitioned from Enbrel® to Benepali® in routine practice, to evaluate safety during and following the transition from Enbrel to Benepali and to evaluate patient-reported outcomes during and following the transition from Enbrel to Benepali.

Conditions

Interventions

BIOLOGICAL

Benepali

As specified in the treatment arm

BIOLOGICAL

Enbrel

As specified in the treatment arm

Sponsors & Collaborators

  • Samsung Bioepis Co., Ltd.

    collaborator INDUSTRY

  • Biogen

    lead INDUSTRY

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-11-30
Completion
2018-11-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03100734 on ClinicalTrials.gov